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ementia can be defined as a clinical syndrome
characterized by a cluster of symptoms and signs mani-
fested by difficulties in memory, disturbances in language
and other cognitive functions, changes in behaviors, and
impairments in activities of daily living. Alzheimer’s dis-
ease (AD), which is named after the German psychiatrist
Alois Alzheimer, who first described this disorder more
than one century ago, is the most common cause of
dementia, accounting for up to 75% of all dementia cases.
Alzheimer’s disease is a progressive neurodegenerative
disorder. During the last a few decades, research in epi-
demiology of dementia and AD has made tremendous
progress. In this review, we briefly summarize the major
findings from the recent epidemiologic studies of AD
concerning occurrence (global prevalence, incidence, and
impact), determinants (risk and protective factors), and
possible strategies toward intervention.
Global population aging, occurrence, and
impact of Alzheimer’s disease
Worldwide population aging 
Population aging has become a worldwide universal phe-
nomenon. The reports from the UN Aging Program and
the US Centers for Disease Control and Prevention have
projected that the number of older people (65+ years) in
the world is expected to increase from 420 million in 2000
to nearly 1 billion by 2030, with the proportion of older
people being increased from 7% to 12%.
1,2 Developing
countries will see the largest increase in absolute num-
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More than 25 million people in the world today are
affected by dementia, most suffering from Alzheimer’s
disease. In both developed and developing nations,
Alzheimer’s disease has had tremendous impact on the
affected individuals, caregivers, and society. The etiolog-
ical factors, other than older age and genetic suscepti-
bility, remain to be determined. Nevertheless, increasing
evidence strongly points to the potential risk roles of vas-
cular risk factors and disorders (eg, cigarette smoking,
midlife high blood pressure and obesity, diabetes, and
cerebrovascular lesions) and the possible beneficial roles
of psychosocial factors (eg, high education, active social
engagement, physical exercise, and mentally stimulating
activity) in the pathogenetic process and clinical mani-
festation of the dementing disorders. The long-term
multidomain interventions toward the optimal control
of multiple vascular risk factors and the maintenance of
socially integrated lifestyles and mentally stimulating
activities are expected to reduce the risk or postpone the
clinical onset of dementia, including Alzheimer’s disease.  
© 2009, LLS SAS Dialogues Clin Neurosci. 2009;11:111-128.bers of older persons. Thus, the developing nations’ share
of the worldwide aging population will increase from
59% to 71%. Because occurrence of AD is strongly asso-
ciated with increasing age, it is anticipated that this
dementing disorder will pose huge challenges to public
health and elderly care systems in all countries across the
world.
Prevalence of Alzheimer’s disease
The pooled data of population-based studies in Europe
suggests that the age-standardized prevalence in people
65+ years old is 6.4% for dementia and 4.4% for AD.
3 In
the US, the study of a national representative sample of
people aged >70 years yielded a prevalence for AD of
9.7%.
4Worldwide, the global prevalence of dementia was
estimated to be 3.9% in people aged 60+ years, with the
regional prevalence being 1.6% in Africa, 4.0% in China
and Western Pacific regions, 4.6% in Latin America,
5.4% in Western Europe, and 6.4% in North America.
5
More than 25 million people in the world are currently
affected by dementia, most suffering from AD, with
around 5 million new cases occurring every year.
5-7The
number of people with dementia is anticipated to double
every 20 years. Despite different inclusion criteria, sev-
eral meta-analyses and nationwide surveys have yielded
roughly similar age-specific prevalence of AD across
regions (Figure 1).
3,4,8,9The age-specific prevalence of AD
almost doubles every 5 years after aged 65. Among
developed nations, approximately 1 in 10 older people
(65+ years) is affected by some degree of dementia,
whereas more than one third of very old people (85+
years) may have dementia-related symptoms and
signs.
10,11There is a similar pattern of dementia subtypes
across the world, with AD and vascular dementia, the
two most common forms of dementia, accounting for
50% to 70% and 15% to 25%, respectively, of all demen-
tia cases. 
Epidemiologic research of dementia and AD in low- and
middle-income countries has drawn much attention in
recent years. A systematic review estimated that the over-
all prevalence of AD in developing countries was 3.4%
(95% CI, 1.6%–5.0%).
12The 10/66 Dementia Research
Group found that the prevalence of dementia (DSM-IV
criteria) in people aged 65+ years in seven developing
nations varied widely from less than 0.5% to more than
6%, which is substantially lower than in developed coun-
tries.
13 Indeed, the prevalence rates of dementia in India
and rural Latin America were approximately a quarter
of the rates in European countries. However, the preva-
lence of AD in persons 65+ years in urban areas of China
was 3.5%, and even higher (4.8%) after post-hoc correc-
tion for negative screening errors,
14 which is generally
comparable with those from Western nations. Similar
prevalence rates of dementia were also reported from the
urban populations of Latin American nations such as
Havana in Cuba (6.4%) and São Paulo in Brazil
(5.1%).
9,15
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Selected abbreviations and acronyms
AD Alzheimer’s disease
APOE apolipoprotein E
BMI body mass index
ELF-EMF extremely-low-frequency electromagnetic
fields
HYVET-COG Hypertension in the Very Elderly Trial-
Cognitive Function Assessment
MCI mild cognitive impairment
PROGRESS Perindopril Protection Against Recurrent
Stroke Study
SCOPE Study on Cognition and Prognosis in the
Elderly
SHEP Systolic Hypertension in the Elderly
Program
Syst-Eur Systolic Hypertension in Europe Trial
WHI-MS Women’s Health Initiative-Memory Study
Figure 1. Age-specific prevalence of Alzheimer’s disease (per 100 popu-
lation) across continents and countries. *, prevalence of all types
of dementia
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USA, 2007Incidence of Alzheimer’s disease
The pooled incidence rate of AD among people 65+
years of age in Europe was 19.4 per 1000 person-years.
16
The pooled data from two large-scale community-based
studies of people aged 65+ years in the US Seattle and
Baltimore areas yielded an incidence rate for AD of 15.0
(male, 13.0; female, 16.9) per 1000 person-years.
17,18The
incidence rate of AD increases almost exponentially with
increasing age until 85 years of age (Figure 2).
16,18-20
However, it remains uncertain whether the incidence
continues to increase, even at more advanced ages, or
reaches a plateau at a certain age; this is relevant for pro-
jecting the burden of the disease as well as for under-
standing its etiology. For instance, a consistently exponen-
tial increase with advancing age in Alzheimer incidence
suggests that AD is an inevitable consequence of aging,
whereas a convergence to or a decline at certain age may
suggest that very old people may have reduced vulnera-
bility, owing perhaps to genetic or environmental fac-
tors.
21 The Cache County Study further found that the
incidence of AD increased with age, peaked, and then
started to decline at extreme old ages for both men and
women.
21 However, some meta-analyses and large-scale
studies in Europe provided no evidence for the potential
decline in the incidence of dementia and AD among the
oldest-old age groups.
16,22,23 The apparent decline sug-
gested in some studies may be an artifact of poor
response rate and survival effect in these very old age
groups. Several studies from Europe observed a higher
incidence rate of AD among women than men, especially
among the oldest-old age groups,
16 whereas studies in
North America generally found no significant gender dif-
ference.
17,18
There appears to have been some geographic variations
in the incidence of AD. The pooled data of eight
European studies suggested a geographical dissociation
across Europe, with higher incidence rates being found
among the oldest-old people of north-western countries
than among southern countries.
16The incidence rates of
AD were reported to be slightly lower in North America
than in Europe. Differences in methodology (eg, differ-
ences in study design and procedure of case ascertain-
ment), rather than real different regional distributions of
the disease, may be partly responsible for the geographic
variations. The study using identical methods in UK
found no evidence of variation in dementia incidence
among five areas in England and Wales.
22 Studies have
confirmed that AD incidence in developing countries is
generally lower than in North America and Europe. For
example, the incidence rate of AD among people aged
65+ years was 7.7 per 1000 person-years in Brazil and 3.2
per 1000 person-years in India.
12,24
Impact of Alzheimer’s disease at individual and 
societal levels
At the individual level, AD significantly shortens life
expectancy and is one of the principal causes of physical
disability, institutionalization, and decreased quality of life
among the elderly. First, AD is strongly associated with
functional disability and institutionalization. It is estimated
that among individuals over 60 years of age dementia con-
tributes 11.2% of the years lived with disability, compared
with 9.5% for stroke, 8.9% for musculoskeletal disorders,
and 5.0% for cardiovascular disease.
25The follow-up stud-
ies of people aged 75+ years in Sweden have shown that
approximately half of the elderly people who develop
functional dependence over a 3-year period can be attrib-
utable to dementia and AD.
26 In many industrialized coun-
tries, dementia is the most common disease among older
adults living in nursing homes or in institutions. Second,
epidemiologic studies have confirmed the malignant
nature of AD that could confers an excess risk of death for
older people in a similar extent to that of malignant
tumors.
27 Several community-based follow-up studies of
Epidemiology of Alzheimer’s disease - Qiu et al Dialogues in Clinical Neuroscience - Vol 11 . No. 2 . 2009
113
Figure 2. Age-specific incidence of Alzheimer’s disease (per 1000 person-
years) across continents and countries. *, incidence of all types
of dementia 
USA, 2002
Age (y)
I
n
c
i
d
e
n
c
e
 
p
e
r
 
1
0
0
0
 
p
e
r
s
o
n
-
y
e
a
r
s
0
10
20
30
40
50
60
70
65-69 70-74 75-79 80-84 85-89 90+
Canada*, 2000
East Asia, 1998
Europe, 2000incident cases showed that AD was associated with a two-
to fivefold increased risk of death.
28,29The long-term fol-
low-up study also showed that AD was associated with rel-
ative risk of 2.6 for mortality, although the strength of asso-
ciation was diluted after controlling for multimorbidities.
30
Overall, the median survival time for people with newly
diagnosed AD ranges from 3 to 6 years.
28 Older age, male
sex, white race, low education, comorbidities (eg, hyper-
tension, diabetes, and heart disease), poorer cognitive
function, and physical disability are frequently reported to
predict a shorter survival in persons with AD.
28-32
The rapid increase in the number of patients with demen-
tia and AD will result in tremendous consequence for our
society and economy. The number of persons with AD in
the US population in 2000 was estimated to be 4.5 million,
and by 2050 this number was projected to increase by
almost threefold, to 13.2 million.
33The more recent study
indicated that in 2006 the worldwide total number of
patients with AD was 26.6 million, and by 2050 the num-
ber will quadruple.
7 It was estimated that about 43% of
AD patients require a high level of care such as nursing
home and institutions. The long-term institutional care will
be the main cost in many developed countries, whereas in
developing countries informal home care provided by
family members is usually the only source available for
patients with dementia.
12 Even in the US, almost 10 million
Americans (eg, family members, friends, and neighbors)
provided unpaid care for persons with AD or other
dementia.
34Thus, enormous resources will be needed for
adequate care of Alzheimer and dementia patients. The
worldwide overall societal costs of dementia were esti-
mated to be more than US$315 billion in 2005, including
one third for informal care;
35 approximately three fourths
of the global costs for dementia occurred in middle-
income countries where about 46% of dementia patients
reside.
12The 2009 reports from Alzheimer’s Association
showed that in US the annual costs for patients with AD
and other dementia were estimated to be US$148 billion
plus US$94 billion unpaid care service, and that AD tripled
health care costs for Americans aged 65+ years.
34 It has
reported that the costs for dementia are higher than those
related to diabetes and smoking.
36 Thus, AD will place
heavy economic burden on the family and society due to
the needs of persistent care and therapy. It was anticipated
that modest advances in therapeutic and preventive strate-
gies that lead to even a 1-year delay in the onset and pro-
gression of clinical AD, would significantly reduce the
global burden of this disease.
7,37
Determinants of Alzheimer’s disease
Alzheimer’s dementia is a multifactorial disease, in which
older age is the strongest risk factor, suggesting that the
aging-related biological processes may be implicated in
the pathogenesis of the disease. Furthermore, the strong
association of AD with increasing age may partially
reflect the cumulative effect of different risk and protec-
tive factors over the lifespan, including the effect of com-
plex interactions of genetic susceptibility, psychosocial
factors, biological factors, and environmental exposures
experienced over the lifespan. Following various etiologic
hypotheses, Table I summarizes the major risk and pro-
tective factors for AD.
38 Moderate to strong evidence,
most from epidemiologic, neuroimaging, and neu-
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Etiologic hypothesis Contents: risk and protective factors Epidemiologic evidence
Genetic susceptibility Risk factors: APOE ε4 allele and familial aggregation Strong
Vascular pathway hypothesis Risk factors: midlife high blood pressure and high BMI, diabetes,  Moderate or sufficient
cerebrovascular disease, and smoking;
Protective factors: light-to-moderate alcohol consumption, and 
antihypertensive therapy
Psychosocial hypothesis Protective factors: high educational attainment, mentally stimulating  Moderate or sufficient
activities, social activity and enriched social network, and physical activity
Nutritional and dietary  Risk factors: deficiency in folate, vitamin B12, and antioxidants 
hypothesis (vitamins A, E, and C); Insufficient or limited/mixed
Protective factors: Fish (omega-3 fatty acids) and vegetable consumption. 
Others (eg, toxic or  Risk factors: traumatic head injuries, occupational exposure to toxins  Insufficient or limited/mixed
inflammatory factors)  and electromagnetic fields, depression, and hormone replacement therapy; 
Protective factors: nonsteroidal anti-inflammatory drugs
Table I. Summary of risk and protective factors for Alzheimer’s disease by various etiologic hypotheses.ropathological research, supports the role of genetic, vas-
cular, and psychosocial factors in the development of
AD, whereas evidence for the etiologic role of other fac-
tors (eg, dietary or nutritional factors, occupational expo-
sures, and inflammation) is mixed or insufficient. 
Genetic hypothesis 
Early-onset familial AD is often caused by autosomal
dominant mutations (eg, mutations in amyloid precursor
protein, presenilin-1, and presenilin-2 genes), which
accounts for only about 2% to 5% of all Alzheimer
patients.
39The majority of AD cases are sporadic and pre-
sent considerable heterogeneity in terms of risk factor
profiles and neuropathological features. First-degree rel-
atives of Alzheimer patients have a higher lifetime risk
of developing AD than the general population or rela-
tives of nondemented individuals
40; both genetic and
shared environmental factors contribute to the phenom-
enon of familial aggregation. In addition, some studies
suggest that the familial aggregation of AD can only be
partially explained by known genetic components such
as the apolipoprotein E (APOE) ε4  allele, indicating that
other susceptibility genes may be involved.
41The APOE
ε4 allele is the only established genetic factor for both
early- and late-onset AD; it is a susceptibility gene for
AD, being neither necessary nor sufficient for AD devel-
opment. With increasing number of the APOE ε4 alleles,
the risk of AD increases and the age of AD onset
deceases, in a dose-dependent manner.
42The risk effect
of APOE ε4 allele on AD decreases with increasing age,
and overall approximately 15% to 20% of Alzheimer
cases are attributable to the ε4 allele.
39,42 Several other
candidate genes, many of them vascular related such as
angiotensin-I converting enzyme, cholesterol 24-hydrox-
ylase, and insulin-degrading enzyme genes, have been
studied, but with inconsistent findings.
44,45
Vascular pathway hypothesis 
Moderate to strong evidence from multidisciplinary
research (epidemiologic, neuroimaging, and neuropatho-
logical studies) has emerged supporting the hypothesis
that vascular risk factors (eg, smoking, obesity, and high
total cholesterol) and vascular morbidity (eg, high blood
pressure, diabetes, and silent brain infarcts and white
matter lesions) are associated with an increased risk of
dementia, including AD. 
Tobacco use
Earlier cross-sectional studies often reported lower preva-
lence rates of AD among smokers than nonsmokers.
46
However, this protective effect was probably due to selec-
tive survival bias related to smoking because smokers are
proportionally less numerous among prevalent cases;
when incident AD cases were examined, such an effect
was no longer present.
47-49 Contrary to the cross-sectional
studies, many follow-up studies found a significantly
increased risk of AD associated with cigarette smoking,
especially among noncarriers of the APOE ε4 allele.
50-52
Meta-analyses of follow-up studies concluded that current
smoking was associated with an increased risk of AD
(pooled relative risk, 1.79; 95% CI, 1.43–2.23).
53,54Thus, in
contrast to the initial hypothesis of a possible protective
effect, cigarette smoking actually increases the risk of AD.
Alcohol consumption
It is known that alcohol abuse can cause “alcoholic
dementia.” The deleterious effect of heavy alcohol intake
emerges from a study suggesting that heavier drinkers at
middle age had a more than threefold increased risk of
dementia and AD in late life, especially among carriers
of the APOE ε4 allele.
55 By contrast, light-to-moderate
alcohol consumption was frequently reported to be asso-
ciated with a reduced incidence of dementia and AD,
56,57
leading to the hypothesis that light-to-moderate alcohol
intake may protect against the development of demen-
tia. However, the role of moderate alcohol consumption
in dementia remains controversial because the inverse
association may be due to information bias, the con-
founding of healthy lifestyles and high socioeconomic
status, different approaches in assessments of alcohol
consumption, or outcome misclassification. 
Indeed, alcohol may have beneficial influences on sev-
eral cardiovascular factors, including lipid and lipopro-
tein levels, and inflammatory, and hemostatic factors.
Moderate alcohol drinking has been related to a reduced
risk of cardiovascular diseases, and may be associated
with fewer brain infarcts. Furthermore, a U-shaped rela-
tionship of alcohol consumption with the burden of white
matter lesions has been described.
58 On the other hand,
excessive alcohol drinking has clear detrimental effects
on the brain, and even light-to-moderate alcohol drink-
ing has been related to increased brain atrophy and to
smaller brain volumes.
59,60
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115Overweight and obesity
The lifespan-dependent relationship between body mass
index (BMI) and risk of dementia has emerged in a sys-
tematic review such that a higher BMI in midlife is a risk
factor for AD and dementia, whereas an accelerated
decline in BMI during late life may anticipate the occur-
rence of the dementing disorders.
61A higher BMI or obe-
sity (especially central obesity) at the age of around 50
years was related to an increased risk of dementia occur-
ring 20 to 25 years later.
62-65 The long-term follow-up
study of Japanese-American men revealed a greater
decline in BMI approximately 10 years prior to demen-
tia onset.
66 The Cardiovascular Health Study also pro-
vided insight into the age-dependent BMI-dementia rela-
tionship, in which obesity at midlife (around 50 years of
age) was related to a higher risk of late-life development
of dementia, whereas BMI measured after age 65 years
was inversely related to dementia risk.
65 In line with these
findings, several follow-up studies of older people sug-
gested that accelerated decline in BMI was associated
with future development of AD.
67-69 Low BMI in late life
was related to a higher risk for AD over a subsequent 5-
to 6-year period.
70,71Thus, late-life low BMI and weight
loss can be interpreted as markers for preclinical AD,
particularly when measured just a few years prior to clin-
ical diagnosis of the disease. 
Blood pressure and blood pressure-lowering therapy
Elevated blood pressure in middle age, especially uncon-
trolled midlife high blood pressure, was linked to an
increased risk of late-life AD in several observational
studies.
72,73 Findings from follow-up studies of late-life
blood pressure in relation to the risk of dementia have
been inconsistent; several follow-up studies, especially
those with a relatively short period of follow-up (eg, <3
years), found no association or even an inverse associa-
tion between level of blood pressure and risk of demen-
tia and AD.
74As dementia has a long latent period and
blood pressure may be lowered at its preclinical phase,
the lack or an inverse association can be interpreted as a
consequence of the disease process.
75,76 However, studies
with a longer follow-up period follow-up (eg, >6 years)
have also reported an inverse association,
77-79 suggesting
that low blood pressure in late life may contribute to the
development or clinical expression of dementia and
AD.
74,80
Longitudinal studies repeatedly show a protective effect
of use of antihypertensive drugs against dementia and
AD.
74,81,82 Recent follow-up studies have suggested that
the protective effect of antihypertensive therapy on
dementia and AD may depend on the duration of treat-
ment and the age when people take the medications; the
more evident efficacy was seen among younger-old peo-
ple (eg, <75 years) and those with long-term treatment.
83,84
Evidence from clinical trials of antihypertensive therapy
and dementia is summarized in the section on interven-
tion trials towards primary prevention. Antihypertensive
treatment may protect against dementia and AD by post-
poning atherosclerotic process, reducing the number of
cerebrovascular lesions, and improving cerebral perfu-
sion.
74 It has also been suggested that some antihyperten-
sive agents (eg, calcium-channel antagonists) may have
neuroprotective effects. The recent neuropathological
study found substantially less Alzheimer neuropatholog-
ical changes (ie, neuritic plaque and neurofibrillary tan-
gle densities) in the medicated hypertension group than
nonhypertensive group, which may reflect a salutary
effect of antihypertensive therapy against AD-associated
neuropathology.
85
High serum cholesterol and use of cholesterol-lowering
drugs (statins)
High serum total cholesterol at midlife was linked to an
increased risk of late-life AD.
86,87The late-life high choles-
terol in relation to dementia and AD is less clear, with
studies indicating either no association or an inverse asso-
ciation of hypercholesterolemia with subsequent develop-
ment of AD.
88-90 A bidirectional influential relationship
between serum total cholesterol and dementia has been
suggested; high total cholesterol at middle age is a risk fac-
tor for the development of AD and dementia 20 years
later, but decreasing serum cholesterol after midlife may
reflect ongoing disease processes and may represent a
marker for late-life AD and dementia.
91 A pattern of
decrease in blood pressure and BMI from midlife to older
adults has also been described, but decline in total choles-
terol shows somewhat different patterns. The dementia-
associated additional decline in blood pressure and BMI
generally becomes detectable about 3 to 6 years before the
clinical expression of the disease, while the decline in total
cholesterol seems to start much earlier, and with less evi-
dent acceleration prior to dementia onset.
92These changes
may explain, at least partly, the inconsistent results from
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as studies having the measurement of serum cholesterol
later in life. 
Little information is currently available regarding the
roles of subtype cholesterols (low-density lipoprotein,
high-density lipoprotein, and triglycerides) in AD. It is
important to note that serum and brain cholesterol are
two separate pools, and links between them are not
totally understood. One possible pathway is represented
by oxysterols, mono-oxygenated metabolites of choles-
terol, with the unique ability to cross the blood-brain bar-
rier.
93The currently available epidemiological and clini-
cal data on use of lipids lowering drugs (statins) and risk
of AD give a rather mixed picture. Several cross-sectional
and case-control studies have reported that statin users
have a considerable lower prevalence of AD.
94,95 While
the follow-up data from the Rotterdam Study showed
that use of statins was associated with a lower risk of AD
independent of lipophilicity of statins,
96 other prospective
studies have indicated that there is no beneficial effect or
only modestly decreased risk of AD related to statin
use.
97,98 Neuropathological studies also showed inconsis-
tent findings as to whether the use of statins was associ-
ated with the burden of Alzheimer pathological changes
and infarcts in the brain.
99,100 Experimental studies suggest
that statins may reduce β-amyloid production in vitro
and in vivo. Statins also have a variety of actions that may
benefit the central nervous system and reduce the risk of
AD, including endothelial protection via actions on the
nitric oxide synthase system, antioxidant, anti-inflamma-
tory, and antiplatelet effects.
Nutritional and dietary factors
Several follow-up studies have reported a decreased risk
of AD associated with increasing dietary or supplementary
intake of antioxidants (eg, vitamins E and C),
101,102 although
some negative findings were also reported.
103 Furthermore,
studies found that higher adherence to “Mediterranean
diet” (ie, a dietary pattern with higher intake of fish, fruits,
and vegetables rich in antioxidants) was associated with a
reduced risk of AD independent of vascular pathways.
104,105
In addition, mixed results have been reported on the asso-
ciation of serum vitamin B12, folate, and homocysteine
with the risk of dementia and AD.
106The Cochrane system-
atic review concluded that folic acid and vitamin B12 sup-
plementations have no benefits on cognition, although
folate plus vitamin B12 are effective in reducing serum
homocysteine.
107 Finally, it has been reported that a diet rich
in saturated fats and cholesterol increases the risk of AD,
108
whereas polyunsaturated fatty acids and fish may be pro-
tective against dementia.
109,110
Unsaturated fatty acids may confer protection through
anti-inflammatory properties. Fatty acids may also play a
part in the synthesis and fluidity of nerve cell membranes
and for synaptic plasticity and neuronal degeneration. In
addition, oxidative stress is one of the central features in
the Alzheimer brain. Thus, it may be plausible that supple-
mentation or diet rich in antioxidants such as fruits, veg-
etables, and vitamins E and C might protect against AD. 
Diabetes
An increased risk of not only vascular dementia but also
neurodegenerative type dementia among persons with
diabetes has been reported in several longitudinal stud-
ies,
111-113 and the risk effect was confirmed by a systematic
review.
114 Midlife diabetes or a longer duration of dia-
betes may play a crucial role in dementia and AD.
115,116 In
addition, borderline or prediabetes or impaired glucose
tolerance is also linked to an increased risk of dementia
and AD in very old people.
117 Such an association may
reflect a long-term direct effect of uncontrolled hyper-
glycemia on neurodegenerative changes in the brain or
an effect of hyperinsulinemia or impaired insulin
response, or due to diabetes-related comorbidities such
as hypertension and dyslipidemia.
118-120
The metabolic syndrome, which is a cluster of multiple
vascular risk factors characterized by abnormalities in
insulin, blood glucose, lipoprotein metabolism, hyperten-
sion, and obesity, was found to be associated with an
increased prevalence of AD in an elderly Finnish popu-
lation.
121 However, the follow-up study of multiethnic
elderly cohort in the US found no association of the
metabolic syndrome with either prevalent or incident
AD, but two components of the syndrome, diabetes and
hyperinsulinemia, were associated with an increased risk
of incident AD
122; the authors concluded that examining
diabetes and hyperinsulinemia separately might be
preferable to using the metabolic syndrome as a single
factor to define the risk of AD.
Cerebral and cardiovascular disease
Stroke, and even clinically silent brain infarcts and
white-matter hyperintensities seen on magnetic
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117resonance imaging   (MRI) scans, significantly increased
the risk of dementia and AD,
123,124 although the observed
association with AD has been argued to actually reflect
an association with mixed dementia. The follow-up data
of the Cardiovascular Health Study showed that cardio-
vascular disease was associated with an increased inci-
dence of dementia and AD, with the highest risk of
dementia being seen in people with peripheral arterial
disease, suggesting that extensive peripheral atheroscle-
rosis is a risk factor for AD.
125,126 Other cardiovascular
disease (eg, atrial fibrillation and heart failure) and more
severe atherosclerosis measured with ankle-to-brachial
index have been related to dementia and to AD as
well.
127-129 Neuropathological studies suggested that cere-
brovascular lesions, atherosclerosis, and neurodegener-
ative changes in the brain often coexist, and may be
coincident processes converging to cause additive dam-
age to the aging brain and to promote clinical expression
of the dementia syndrome.
130,131
Psychosocial hypothesis 
A systematic review found that psychosocial factors and
actively integrated lifestyle over the lifespan may reduce
the risk of AD and dementia.
132 These factors include
early-life high educational attainment, adult-life high
work complexity, late-life rich social network and high
levels of social engagement, and more frequently partic-
ipating in physically and mentally stimulating activity. 
High educational attainments and socioeconomic status
An association of low education with an increased risk
of dementia and AD has been reported in numerous
cross-sectional and longitudinal studies.
133,134 Education
and socioeconomic status are highly correlated; when
both measures were examined simultaneously, the
independent association was detected only with educa-
tion.
135 The reserve hypothesis has been proposed to
interpret this association such that education could
enhance neural and cognitive reserve that may provide
compensatory mechanisms to cope with degenerative
pathological changes in the brain, and therefore delay
onset of the dementia syndrome.
136 Alternatively, edu-
cational achievement may be a surrogate or an indica-
tor of intelligent quotient, early life living environ-
ments, and occupational toxic exposure experienced
over adulthood.
133
Social network and social engagement
Evidence from longitudinal observational studies sug-
gests that a poor social network or social disengagement
is associated with cognitive decline and dementia.
132,137
The risk for dementia and AD was also increased in
older people with increasing social isolation and less fre-
quent and unsatisfactory contacts with relatives and
friends. Furthermore, a recent study suggested that low
neuroticism in combination with high extraversion was
the personality trait associated with the lowest dementia
risk, and among socially isolated individuals even low
neuroticism alone seemed to decrease the risk of demen-
tia.
138 Finally, low social engagement in late life and a
decline in social engagement from middle age to late life
were associated with a doubly increased risk of develop-
ing dementia and AD in late life.
139,140 Rich social net-
works and high social engagement imply better social
support, leading to better access to resources and mate-
rial goods. Rich and large social networks also provide
affective and intellectual stimulation that could influence
cognitive function and different health outcomes through
behavioral, psychological, and physiological path-
ways.
132,141
Physical activity
Regular physical exercise was reported to be associated
with a delay in onset of dementia and AD among cogni-
tively healthy elderly.
142 In the Kungsholmen Project, the
component of physical activity presenting in various
leisure activities, rather than sports and any specific phys-
ical exercise, was related to a decreased dementia
risk.
143In addition, low-intensity activity such as walking
may reduce the risk of dementia and cognitive decline.
144
A strong protective effect of regular physical activity in
middle age against the development of dementia and AD
in late life was reported, especially for persons with the
APOE ε4 allele.
145As it may take years to achieve high
levels of physical fitness, brief periods of exercise train-
ing may not have substantial benefits on cognitive
processes, but could still be detectable in the subsets of
cognitive domains that are more sensitive to the age-
related decrements. Physical activity is important not
only in promoting general and vascular health, but also
in promoting brain plasticity, and it may also affect sev-
eral gene transcripts and neurotrophic factors that are
relevant for the maintenance of cognitive functions.
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Various types of mentally demanding activities have been
examined in relation to dementia and AD, including knit-
ting, gardening, dancing, playing board games and musi-
cal instruments, reading, social and cultural activities, and
watching specific television programs, which often
showed a protective effect.
147,114 Due to the cultural and
individual differences in choosing specific activities, some
researchers summarize mentally stimulating activities
into a composite score, which showed that a cognitive
activity score involving participation in seven common
activities with information processing as a central com-
ponent was associated with a reduced risk of AD, even
after controlling for APOE ε4 allele, medical conditions,
and depressive symptoms.
148,149The Swedish Twin Study
showed that greater complexity of work, and particularly
complex work with people, may reduce the risk of AD.
150
The Canadian Study of Health and Aging found that
high complexity of work appeared to be associated with
a reduced risk of dementia, but mostly for vascular
dementia.
151 In supporting of these findings, the recent
neuroimaging study suggested that a high level of com-
plex mental activity across the lifespan was correlated
with a reduced rate of hippocampal atrophy.
152
Other etiologic hypotheses (inflammation, 
toxic exposure, and other factors) 
Inflammation
A higher level of serum C-reactive protein (CRP) in
midlife was linked to an increased risk of both Alzheimer
type and vascular dementias, suggesting that inflammatory
markers may reflect both peripheral disease and cerebral
mechanisms related to dementia, and that these processes
are measurable for a long time before dementia is mani-
fested.
153 Follow-up studies of older adults also showed an
association of serum inflammatory markers (eg, CRP and
interleukin-6) measured at older ages with an increased
incidence of dementia and AD.
154,155As additional evidence
supporting the inflammatory involvement in AD and
dementia, recent follow-up studies and the systematic
review of observational studies concludes that long-term
use of nonsteroidal anti-inflammatory drugs (NSAIDs)
(eg, >2 years) may have beneficial effect against AD and
dementia.
156,157 In addition, experimental research found
that neuritic plaques in the brain are associated with
inflammatory proteins. Therefore, it seems plausible to
hypothesize that inflammatory mechanisms may play a
role in the processes leading to neurodegeneration.
However, neuropathological studies found no evidence for
an association between use of NSAIDs and reduced bur-
den of AD pathological changes.
158 Furthermore, the
results from the clinical trial of anti-inflammatory drugs
(celecoxib or naproxen) in AD prevention, which was sus-
pended due to increased cardiovascular risks associated
with celecoxib, failed to show any beneficial effect of using
these drugs against AD, instead, an increased risk for AD
related to drug therapy were observed (see section on
Intervention trials toward primary prevention).
159-161
Toxic exposures
Manual work as the lifetime principal occupation has
been related to AD and dementia in some studies,
162 sug-
gesting a possible implication of occupational toxic expo-
sures in the development of the dementia disorders.
Occupational exposures to heavy metals such as alu-
minum and mercury have been suggested as a risk factor
for AD, and even high consumption of aluminum from
drinking water may be a risk factor for AD.
163 However,
this has not been confirmed.
164 In addition, occupational
exposure to extremely-low-frequency electromagnetic
fields (ELF-EMF) has been related to an increased risk
of dementia and AD in a number of follow-up stud-
ies.
165,166The meta-analysis of epidemiological evidence
suggests an association between occupational exposure
to ELF-EMF and AD.
167The biological plausibility link-
ing ELF-EMF to AD has been previously described.
168
Other factors
First, traumatic brain injury has been extensively investi-
gated as a possible risk factor for AD. The meta-analysis
of case-control studies supported an association between
a history of previous head injury and the risk of develop-
ing AD.
169 In contrast, some longitudinal studies found that
AD risk was not associated with head trauma or associ-
ated with only severe head injury.
170,171 Second, an associ-
ation between hormone replacement therapy and a
reduced risk of dementia and AD among postmenopausal
women had been frequently reported in numerous obser-
vational studies until 2004 when, instead of a protective
effect, a significantly increased risk of dementia associated
with estrogen therapy was found in the Women’s Health
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prevention). Finally, several studies have reported an asso-
ciation between depression and an elevated risk of later
development of dementia and AD, but it remains arguable
as to whether depression is a preclinical symptom or a
pure risk factor for dementia and AD.
172-174
Interventions toward Alzheimer’s disease
Current evidence tends to support the notion that
dementia onset may be postponed by implementing
interventions toward the potential etiologic factors (both
risk and protective factors) (ie, primary prevention) and
by early detection (ie, secondary prevention), whereas
appropriate care and pharmacotherapy for patients with
AD and dementia (ie, tertiary prevention) may help sta-
bilize cognitive functions, reduce agitation, control neu-
ropsychiatric symptoms, and improve the quality of life.
Interventions toward primary prevention 
Primary intervention strategies
Theoretically, even if the mechanisms of vascular and psy-
chosocial factors being involved in the pathogenesis and
clinical expression of AD are still not fully understood, pri-
mary prevention seems possible as most vascular factors
and disorders, psychosocial factors, and lifestyle factors are
modifiable or amenable to management.
38,175 One interven-
tion strategy is to target vascular pathways, including man-
agement of midlife high blood pressure and obesity, high
blood glucose level, and diabetes. In addition, preventing
recurrent cerebrovascular disease and maintaining sufficient
cerebral blood perfusion by adequately managing heart fail-
ure and avoiding very low blood pressure may help post-
pone clinical expression of the dementia syndrome, espe-
cially among very old people. The second strategy is to
maintain the more active and socially integrated lifestyles
by establishing extensive social networks and frequently
participating in social, physical, and intellectually stimulat-
ing activities, which may reduce the risk or delay the onset
of AD.
38,132Taken together, the most effective strategy may
be to encourage people implementing multiple preventive
measures throughout the life course, including high educa-
tional attainment in childhood and early adulthood, active
control of vascular factors and disorders over adulthood,
and maintenance of mentally, physically, and socially active
lifestyles during middle age and later in life.
Intervention trials toward primary prevention
The main clinical and intervention trials toward primary
prevention by targeting the possible risk and protective
factors for AD and dementia are summarized in Table
II.
160,161,176-182Antihypertensive treatments in reducing the
risk of dementia and AD have been tested in a few clin-
ical trials. The pooling analysis of the 2007 Cochrane
review, based essentially on three clinical trials (SHEP,
183
Syst-Eur,
184 and SCOPE
185), found no convincing evi-
dence that blood pressure-lowering therapy among
elderly individuals with hypertension could prevent
dementia. However, in this review the SCOPE trial,
which did not show any effect of blood pressure-lower-
ing treatment by candesartan on the risk of dementia,
was actually not a placebo-controlled trial due to ethi-
cal considerations. By contrast, the placebo-controlled
PROGRESS trial among individuals with cerebrovas-
cular disease (transient ischemic attacks and stroke),
which did find a beneficial effect of antihypertensive
therapy on cognitive function related to recurrent
stroke, was not included.
186 The cognition substudy of
the double-blind placebo-controlled Hypertension in
the Very Elderly Trial (HYVET-COG) among people
80+ years found a nonsignificant reduction in the risk
of dementia related to antihypertensive treatment.
Encouragingly, when data from this clinical trial were
pooled together with those from three other double-
blind placebo-controlled trials (SHEP, Syst-Eur, and
PROGRESS), antihypertensive treatment could reduce
the risk of dementia by 13% (hazard ratio, 0.87; 95%
CI, 0.76–1.00; P=0.045).
177 It is worthwhile to notice that
dementia or AD was the secondary end point in all
major clinical trials of antihypertensive therapy, with a
relatively short period of follow-up because the trials
had to be terminated when benefits of the treatments
were clearly shown in terms of primary end points (usu-
ally cardiac and cerebrovascular disease). In this con-
text, if the beneficial effect of lowering blood pressure
on dementia is not as strong as for cardiovascular dis-
ease, a longer period of observation is needed to
demonstrate any significant beneficial effect. 
Estrogen therapy among postmenopausal women has
been linked to a considerably lower risk of AD and
dementia in numerous observational studies, but the
large-scale clinical trial of the Women’s Health Initiative
Memory Study (WHI-MS) showed that estrogen therapy
alone or in combination with progestin did not reduce
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120incidence of probable dementia and mild cognitive
impairment (MCI); instead, the active treatments with
estrogen and estrogen plus progestin were found to be
associated with a twofold increased risk for both demen-
tia and MCI.
178,179 It has been argued that in the WHI-MS
hormone replacement therapy was given 10 to 15 years
after the menopause when the “window of critical time”
for putative beneficial effects of estrogen therapy may
have been missed.
187
Other major clinical trials of primary prevention against
dementia, such as those with NSAIDs and vitamin E
supplementation, have so far failed to confirm any effi-
cacy against dementia and AD (Table II), while more
clinical trials (eg, use of cholesterol-lowering drugs and
blood glucose lowering drugs) are ongoing.
188,189The lack
of success in most primary prevention trials underscores
the need of new strategies in future intervention stud-
ies.
New strategies for primary prevention: 
a life-course approach and multidomain interventions
The life-course approach considers biological, environmen-
tal, and psychosocial factors acting during early childhood,
middle age, and late life as relevant for the development of
dementia and AD. This approach seeks to identify the
“time windows” when exposures exert the greatest effect
on the development of disease and to determine whether
concurrent exposures could have interactive effects over
the lifespan.
190 In this context, the risk of late-life dementia
and AD is likely to be determined by accumulative effects
or complex interactions of genetic, biological, psychosocial,
and environmental exposures experienced over the life
course. For instance, the brain structural and functional
reserve related to education and other psychosocial factors
can be conceived as the sum of their lifetime input of edu-
cation and related activities.
191 In addition, the life-course
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Authors, years Participants  Interventions Outcomes Main findings
McGuinness et al,
176 2008 n=15295, age ≥60 years, from SHEP,  Blood pressure- Dementia, AD Dementia: HR 0.89 (95% CI 0.69–1.16)
Syst-Eur, and SCOPE Trials lowering therapy AD: HR 0.85 (95% CI 0.63–1.15)
Peters et al,
177 2008 HYVET-COG: n=3336, age ≥80 years Blood pressure-  Dementia  HYVET-COG: HR 0.86 (95% CI 0.67–1.09)
Meta-analysis (SHEP, Syst-Eur,  lowering therapy Meat-analysis: HR 0.87 
PROGRESS, and HYVET-COG):  (95% CI 0.76–1.00), P=0.045
n=16595, age ≥60 years
Shumaker et al,
178 2004; n=7479,  age  ≥65 years, Estrogen alone or  Dementia and  Estrogen: dementia: HR 1.76 
Espeland et al,
179 2004  community-dwelling women  estrogen plus  MCI, cognitive  (95% CI 1.19–2.60);
progestin function dementia or MCI: 1.38 (1.01–1.89)
Estrogen plus progestin: no effect 
on cognition
Heart Protection Study  n=20536, age 40–80 years, had   1. Simvastatin Dementia and  Incidence rates: Treatment vs placebo 
Collaborative Group,
180,181 vascular disease, and total  2. Vitamins E, C,  cognitive  groups: 
2002 cholesterol level ≥3.5 mmol/L and β-carotene impairment For dementia: 0.3% vs 0.3%
For cognitive impairment: 
23.7% vs 24.2%
ADAPT Research Group,
160,161 n=2528, age ≥70 years,  Celecoxib or  AD, cognitive  AD: celecoxib: HR 2.0 
2007; 2008 had a family history of AD naproxen function (95% CI 0.8–5.0, P=0.14); 
naproxen: HR 2.4 
(95% CI 0.95–5.8, P=0.06)
Cognition: cognitive function was 
not improved
DeKosky et al,
182 2008 n=3069, age ≥75 years, with  Extract of Ginkgo  Dementia, AD Dementia: HR 1.12 (95% CI 0.94–1.33)
normal cognition or MCI biloba AD: HR 1.16 (95% CI 0.97–1.39)
Table II. Major clinical trials of primary prevention against dementia and Alzheimer's disease. AD, Alzheimer’s disease; ADAPT, Alzheimer’s Disease Anti-
inflammatory Prevention Trial; CI, confidence interval; HR, hazard ratio; HYVET-COG, Hypertension in the Very Elderly Trial-Cognitive Function
Assessment; MCI, mild cognitive impairment; SCOPE, Study on Cognition and Prognosis in the Elderly; PROGRESS, Perindopril Protection Against
Recurrent Stroke Study; SHEP, Systolic Hypertension in the Elderly Program; Syst-Eur, Systolic Hypertension in Europe. approach model introduces the concept of “time windows”
at exposure, which might be highly relevant for chronic dis-
orders with a long time latent period such as AD.
38A cer-
tain factor might increase the risk of the disease if a subject
is exposed during a specific time period, whereas the same
factor may show a different effect on the disease in another
life period, due to, for example, differential interactions
with other factors or selective survival. For instance, high
blood pressure and high BMI in midlife are risk factors for
late-life dementia, whereas low blood pressure and low
BMI among older people are associated with an increased
risk of dementia and AD.
61,65,74
Furthermore, intervention studies integrating several differ-
ent domains of intervention have not yet been implemented
so far. The disappointing results of previous intervention tri-
als focusing on a single intervention agent or component in
older adults or in already cognitively impaired individuals
point out that a few key issues need to be taken into account
in future trials: (i) time window of interventions—interven-
tions starting earlier in life may be more effective; (ii) target
group—a healthy, relative young population will require rel-
atively long follow-up periods, large sample sizes, and con-
siderable financial resources; and (iii) outcome measures—
cognitive impairment may be better than “conversion” to
clinical dementia. Several multidomain intervention trials
are being planned or ongoing such as the Dose-Response
to Exercise Training (DR’s EXTRA), the Cognitive
Substudy of the Finnish Diabetes Prevention Study, and the
Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability (FINGER). In the FINGER
study, individuals at an increased risk for developing demen-
tia being identified according to the CAIDE Dementia Risk
Score are targeted for intervention.
192The 2-year multido-
main interventions include four main components: (i) nutri-
tional guidance; (ii) physical activity; (iii) cognitive training
and social activity; and (iv) intensive monitoring and man-
agement of metabolic and vascular risk factors. The FIN-
GER study will be the first carefully-designed randomized
intervention trial to clarify to what extent a multidomain
intervention will delay the onset of cognitive impairment
and dementia among persons with an increased risk of the
disease. These data are urgently needed for health educa-
tion and for planning community health service. 
Secondary prevention 
Alzheimer’s disease is characterized by a preclinical
phase, possibly lasting years, during which progressive
neurodegeneration in the brain is occurring before typ-
ical clinical symptoms (eg, cognitive deficits and subtle
cognitive disturbances) become detectable.
193
Theoretically, detection of AD at early stage may provide
an opportunity for implementing therapeutic interven-
tion to more effectively delay its progression to clinical
dementia. However, there remains a challenge as to how
to identify individuals during the preclinical phase of the
disease, although some clinical markers, neuroimaging
biomarkers, and biochemical markers have been investi-
gated.
194 First, numerous studies have suggested that
deficits in specific cognitive domains such as episodic
memory and verbal ability are conceivable up to 10 years
before the dementia syndrome can be clinically diag-
nosed, with a more evident decline occurring over the
final few years. The term “mild cognitive impairment” has
been used in clinical settings to identify individuals with
isolated memory loss (ie, “amnestic” type MCI), which is
more likely to represent the preclinical phase of
Alzheimer dementia. However, population-based follow-
up studies have frequently shown that individuals with
MCI represent a very heterogeneous group in terms of
prognosis
195,196; although elderly persons with MCI had
increased risk of progressing to dementia, a substantial
proportion remained stable or even reverted to normal
during the next few years. Second, biochemical markers
in serum and cerebrospinal fluid such as β-amyloid and
τ-protein have been proposed for early detection of AD,
but these markers are not sufficiently reliable in making
diagnosis of AD in the presymptomatic phase.
39,194 Finally,
during the last decade neuroimaging has emerged as a
useful tool to define AD at both preclinical and early
clinical phases of the disease. For example, the amyloid
positron emission tomography imaging tracer ligands
offer opportunity for measuring β-amyloid in the brain
in vivo, which provides the possibility for early diagnosis
and for monitoring the course of antiamyloid therapy in
AD.
197,198 Furthermore, the medial-temporal lobe atrophy
seen on volumetric MRI has been used in the identifica-
tion of MCI and early AD as well as in the assessment of
progression of MCI and early AD.
199,200 Successful sec-
ondary prevention relies on both reliable detection of the
disease at an early stage and availability of efficacious
interventions for slowing down progression of the dis-
ease. However, while efforts are being made to find ways
to effectively counteract the course of AD, some method-
ological issues facing research on disease-modifying ther-
apies and interventions remain a challenge.
201,202
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The tertiary prevention aims to avoid functional disabil-
ity, and if possible, to improve quality of life for patients
with AD. Cognitive training may help maintain cognitive
function, slow down cognitive decline, and improve well-
being for people with mild dementia. Current medica-
tions widely used for AD and dementia, including
cholinesterase inhibitors (donepezil, rivastigmine, and
galantamine) and the N-methyl-D-aspartate-receptor
antagonist (memantine), are designed to target clinical
symptoms of the disease such as cognitive and neuropsy-
chiatric disturbances.
201The efficacy of antioxidant treat-
ments in AD has not been proven. For example, the
Cochrane review found no evidence of efficacy of vita-
min E in the treatment of AD and in the prevention of
progression of MCI to AD,
203 although the randomized
clinical trials of the Physicians’ Health Study II sug-
gested that a long-term β-carotene supplementation
might provide cognitive benefits among men.
204
Furthermore, high-dose B vitamin supplements did not
slow down cognitive decline among individuals with
mild to moderate AD.
205 Intensive research is ongoing in
an attempt to develop disease-modifying drugs by tar-
geting the key neuropathological processes in AD such
as β-amyloid protein.
206
Summary
Alzheimer’s disease represents an increasing challenge
to public health and the health care system, and has had
tremendous impact at both the individual and the soci-
etal levels. Epidemiologic research has provided suffi-
cient evidence that vascular risk factors in middle-aged
and older adults play a significant role in the develop-
ment and progression of dementia and AD, whereas
extensive social network and active engagement in men-
tal, social, and physical activities may postpone the onset
of the dementing disorder. Multidomain community
intervention trials are warranted to determine to what
extent preventive strategies toward optimal control of
multiple vascular factors and disorders, as well as the
maintenance of an active lifestyle, are effective against
dementia and AD. ❏
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Epidemiología de la Enfermedad de
Alzheimer: frecuencia, determinantes y
estrategias orientadas a la intervención
Hoy en día más de 25 millones de personas en el
mundo están afectadas por demencia, la mayor
parte con Enfermedad de Alzheimer. Tanto en los
países desarrollados como en aquellos en vías de
desarrollo, la Enfermedad de Alzheimer ha tenido
un tremendo impacto en los individuos que la
padecen, en los cuidadores y en la sociedad. Los fac-
tores etiológicos, más allá de la edad avanzada y la
susceptibilidad genética, tienen que ser determina-
dos. Sin embargo, hay una creciente evidencia que
apunta fuertemente al papel potencialmente
dañino de los factores de riesgo vascular y otros
trastornos (fumar cigarrillos, presión alta y obesi-
dad en la edad media de la vida, diabetes y lesiones
cerebrovasculares) y al posible papel benéfico de los
factores psicosociales (mayor escolaridad, participa-
ción social activa, ejercicio físico y actividades de
estimulación mental) en el proceso patogénico y en
las manifestaciones clínicas de las demencias. 
Se espera que las intervenciones a largo plazo,
desde múltiples áreas, orientadas al control óptimo
de los múltiples factores de riesgo vascular y el
mantenimiento de estilos de vida con buena inte-
gración social y actividades de estimulación mental
reduzcan el riesgo o retarden la instalación de las
demencias, incluyendo la Enfermedad de
Alzheimer.   
Épidémiologie de la maladie d’Alzheimer :
survenue, déterminants et stratégies 
d’intervention
Plus de 25 millions de personnes dans le monde
sont aujourd’hui touchées par la démence, la plu-
part par la maladie d’Alzheimer. Cette maladie
affecte de façon très importante les patients
atteints, leurs soignants et la société qu’il s’agisse
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